Fig. 1 · Structure
Documents & Downloads
Fulzerasib (IBI351, GFH925)
KRAS G12C inhibitor
Fulzerasib (GFH925) is an irreversible inhibitor of KRAS^G12C, demonstrating potent anticancer activity. It exhibits synergistic effects when combined with cetuximab, enhancing the therapeutic efficacy against KRAS^G12C-driven tumors.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2641747-54-6 |
| Applications | KRAS G12C inhibitor |
| Formula | C32H30ClFN6O4 |
| Molecular Weight | 617.07 |
| Synonyms | IBI351; GFH925 |
| SMILES | O=C(C=C)N1CCN2C(C3=C(N4C5=C(C(C)C)N=CC=C5C)N=C(C6=C(O)C=CC=C6F)C(Cl)=C3)=C(N(C)C([C@@]2([H])C1)=O)C4=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.